Efficacy News and Research

RSS
Prenatal antipsychotic drug exposure may reduce scores on infant neuromotor screening

Prenatal antipsychotic drug exposure may reduce scores on infant neuromotor screening

TLR4/MD-2 protein complex triggers morphine-induced inflammation

TLR4/MD-2 protein complex triggers morphine-induced inflammation

Combination treatment effective against melanoma

Combination treatment effective against melanoma

Positive outcome from AiCuris’ Letermovir phase 2b trial on HCMV infections

Positive outcome from AiCuris’ Letermovir phase 2b trial on HCMV infections

Non-invasive brain stimulation cuts time to improve speech in stroke patients

Non-invasive brain stimulation cuts time to improve speech in stroke patients

Novel tetracyclines with improved potency, efficacy against contemporary P. aeruginosa isolates

Novel tetracyclines with improved potency, efficacy against contemporary P. aeruginosa isolates

Ampio, Australian TGA reach agreement over Zertane submission plan

Ampio, Australian TGA reach agreement over Zertane submission plan

Clinical data for cabozantinib to be presented at ASCO annual meeting

Clinical data for cabozantinib to be presented at ASCO annual meeting

ViiV, Shionogi announce initial results from dolutegravir Phase III study on HIV-1

ViiV, Shionogi announce initial results from dolutegravir Phase III study on HIV-1

Galeterone safe, effective for patients with CRPC

Galeterone safe, effective for patients with CRPC

Tokai Pharmaceuticals announces data from galeterone Phase 1 trial for CRPC

Tokai Pharmaceuticals announces data from galeterone Phase 1 trial for CRPC

Sleep deprivation does not disturb performance of interventionists during PCI procedures

Sleep deprivation does not disturb performance of interventionists during PCI procedures

UH clinical trial to evaluate stool DNA testing for colon cancer

UH clinical trial to evaluate stool DNA testing for colon cancer

Data from Cempra's CEM-101 Phase 2 trial on N. gonorrhoeae infections to be presented at ECCMID

Data from Cempra's CEM-101 Phase 2 trial on N. gonorrhoeae infections to be presented at ECCMID

Data from Cempra's CEM-101 Phase 2 trial on CABP to be presented at ECCMID

Data from Cempra's CEM-101 Phase 2 trial on CABP to be presented at ECCMID

ImmunoGen commences IMGN901 Phase II evaluation for SCLC

ImmunoGen commences IMGN901 Phase II evaluation for SCLC

Top-line results from Shire's SPD476 phase 3 trial on diverticulitis

Top-line results from Shire's SPD476 phase 3 trial on diverticulitis

Bionovo 2011 total revenues decrease to $0.3 million

Bionovo 2011 total revenues decrease to $0.3 million

AlphaCore Pharma commences ACP-501 Phase 1 study in coronary arterial disease

AlphaCore Pharma commences ACP-501 Phase 1 study in coronary arterial disease

Cancer patients with CDI may benefit from DIFICLIR drug

Cancer patients with CDI may benefit from DIFICLIR drug

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.